8-K: Erasca Reports Positive ERAS-0015 Phase 1 Data

Erasca announced positive preliminary Phase 1 dose escalation data for its pan-RAS molecular glue, ERAS-0015, in patients with RAS-mutant solid tumors.

Summary

• Preliminary Phase 1 data from the AURORAS-1 (US) and JYP0015M101 (China) trials show promising efficacy for ERAS-0015 in KRAS-mutant solid tumors.
• Pharmacokinetics demonstrated dose-dependent exposure with no plateau observed up to the 40 mg maximum administered dose.
• Pharmacodynamic analysis showed 100% of patients (14/14) achieved at least a 75% reduction in KRAS G12X variant allele fraction at PAD doses.
• In NSCLC patients, the unconfirmed objective response rate (uORR) reached 62% in 2L+ settings and 75% in post-ICI/platinum settings.
• In PDAC patients, the uORR reached 40% in 2L settings.
• The company selected 24 mg and 32 mg QD as the go-forward monotherapy recommended doses for expansion (RDEs).

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive update due to the robust clinical response rates and the advancement of the pipeline ahead of schedule, despite the inherent risks of cross-study comparisons.

Positives

• Strong clinical response rates in difficult-to-treat NSCLC and PDAC populations.
• High durability of response, with nearly all responding patients remaining on treatment as of the data cutoff.
• Generally well-tolerated safety profile with no dose-limiting toxicities (DLTs) observed in the monotherapy cohorts.
• Successful demonstration of pharmacodynamic activity with significant ctDNA reduction.
• Early clinical signals of combinability with panitumumab.

Negatives

• One Grade 5 (fatal) adverse event of pneumonitis reported in a heavily pretreated metastatic PDAC patient.
• Reliance on cross-study comparisons against competitors rather than head-to-head clinical trials.
• Data includes pooled results from separate trials with different designs and patient characteristics.

Risks

• Clinical trial outcomes may change as enrollment continues and data matures.
• Unconfirmed partial responses may not translate into confirmed responses.
• Potential for future litigation or intellectual property disputes with Revolution Medicines regarding ERAS-0015.
• The novel approach of targeting the RAS/MAPK pathway remains unproven.
• Potential for unexpected adverse side effects in larger patient populations.

Future Outlook

The company plans to advance ERAS-0015 into monotherapy expansion and combination dose escalation cohorts, with data expected in the first half of 2027. BOREALIS-1 trial data for ERAS-4001 is expected in the second half of 2026.

Management Comments

• The company characterizes ERAS-0015 as a potentially best-in-class, pan-RAS molecular glue.
• Management highlights the potential for ERAS-0015 to serve as a backbone therapy for future combinations.

Industry Context

StockSavvy.ai notes that Erasca is competing in the highly crowded and competitive RAS-inhibitor space, specifically benchmarking against Revolution Medicines' RMC-6236. The ability to demonstrate superior response rates in PDAC and NSCLC is critical for market differentiation in this therapeutic class.

Comparison to Industry Standards

• The reported 62% uORR in 2L+ NSCLC is claimed to exceed the RMC-6236 comparator by 24 percentage points.
• The reported 40% uORR in 2L PDAC is claimed to exceed the RMC-6236 comparator by 11 percentage points.
• Comparisons are based on cross-study analysis, which inherently carries limitations compared to head-to-head trials.

Legal Proceedings

• The company acknowledges ongoing risks related to potential litigation from Revolution Medicines regarding patent infringement or trade secret misappropriation.

Stakeholder Impact

• Shareholders may view the positive clinical data as a significant de-risking event for the company's lead asset.
• Patients with RAS-mutant solid tumors may benefit from the potential availability of a new therapeutic option.

Next Steps

• Continue monotherapy expansion cohorts for ERAS-0015.
• Continue combination dose escalation cohorts for ERAS-0015.
• Report BOREALIS-1 preliminary monotherapy data in 2H 2026.

Key Dates

Recommendation

The strong preliminary efficacy data in high-unmet-need indications like PDAC and NSCLC, combined with the selection of RDEs and accelerated trial timelines, provides a compelling case for institutional accumulation, provided the investor is comfortable with the risks of cross-study comparisons and potential IP litigation.

Keywords

ERAS-0015, Erasca, RAS-mutant, Oncology, KRAS, NSCLC, PDAC, Biotech, Clinical Trials